Mylan Inc. (MYL) will receive a license to sell generic versions of Vivelle-Dot, a treatment for menopause symptoms, after settling a patent litigation lawsuit with Novartis AG's (NVS) Novartis Pharmaceuticals Corp. affiliate.

Pursuant to the agreement, pending litigation will be dismissed and Mylan will receive a license to begin selling generic versions of the product on Dec. 16, 2013, or earlier under certain circumstances.

Further details of the settlement are confidential.

Mylan confirmed in March that the makers of Vivelle-Dot were challenging its application to market a generic version of the drug.

Vivelle-Dot pulled in about $215 million in sales last year, according to IMS Health. Mylan said it believes it was the first company to file a complete abbreviated application for the drug and can qualify for marketing exclusivity within 180 days upon regulatory approval.

Click HERE to read this article in full.